Keywords: AstraZeneca, Brilinta, AHA, Research, FDA filing
AstraZeneca presents strong Ph II results for Brilinta at AHA, beating Plavix; files drug with FDA
Article | 19 November 2009
Anglo-Swedish drug major AstraZeneca announced the results of the Phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (trade name Brilinta) at the annual American Heart Association Scientific Sessions in Orlando, Florida, with the first study’s results being simultaneously published in the medical journal Circulation. The company has also filed for approval of the drug in the USA.
T Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
